Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

  • Track 1-1Concepts in Infectious Disease Research
  • Track 1-2Plants used as bioreactors
  • Track 1-3Preparation of the Vaccine Strain
  • Track 1-4Vaccine database and analysis system
  • Track 1-5Technique Used In vaccines production
  • Track 1-6Challenges Faced in vaccine discovery
  • Track 1-7Vaccine Bulk Manufacture
  • Track 2-1Epitope-focused vaccine design
  • Track 2-2Designing Vaccines in the Era of Genomics
  • Track 2-3Immunological sequences
  • Track 2-4Structural Biology and Pathogen Entry
  • Track 2-5Interactions between Host and Pathogen
  • Track 2-6Combined predictions
  • Track 2-7Economics of development
  • Track 2-8Antigen Selection and Optimization
  • Track 2-9Immune Response Prediction
  • Track 3-1Epidemiology and Methodology 
  • Track 3-2Glycoconjugate Vaccines
  • Track 3-3Hib vaccines
  • Track 3-4Vaccines formulation and technologies used in conjugated vaccines
  • Track 3-5N. meningitides vaccines
  • Track 3-6S. pneumoniae vaccines
  • Track 4-1Clinical development
  • Track 4-2Assay development
  • Track 4-3Vaccine Manufacturing
  • Track 4-4Vaccine Registration and Approval
  • Track 4-5Vaccine Funding
  • Track 4-6Novel discoveries in allergen vaccines
  • Track 5-1Measles Eradication
  • Track 5-2Implementation of ideal vaccines
  • Track 5-3Proper knowledge of vaccines and its uses
  • Track 5-4Polio Eradication and Endgame Strategic Plans
  • Track 5-5Protection against vaccine preventable diseases
  • Track 5-6Quality control and assurance of Vaccines
  • Track 6-1Chickenpox vaccines
  • Track 6-2Diphtheria vaccines
  • Track 6-3Varicella vaccines
  • Track 6-4Human papillomavirus (HPV) vaccines
  • Track 6-5Zoster vaccines
  • Track 6-6Measles, mumps, rubella (MMR) vaccines
  • Track 6-7Pneumococcal vaccines
  • Track 7-1Vaccine administration
  • Track 7-2Timing and spacing of vaccine doses
  • Track 7-3Observation of precautions and contraindications
  • Track 7-4Communication about vaccine benefits and risks
  • Track 7-5Develop and maintain Emergency vaccine retrieval
  • Track 7-6Training and education for proper storage
  • Track 7-7Vaccine Inventory Management, Transport, and Preparation
  • Track 8-1Cholera vaccine
  • Track 8-2Yellow fever Vaccine
  • Track 8-3Bacterial Infection
  • Track 8-4Pertussis (whooping cough) Vaccine
  • Track 8-5Tetanus Vaccine
  • Track 8-6Plague Vaccine
  • Track 8-7Influenza Vaccine
  • Track 9-1Vaccines: A boon or curse
  • Track 9-2Adverse drug reaction
  • Track 9-3Vaccine Safety Programs
  • Track 9-4Development of Pandemic Vaccines
  • Track 9-5Current issues
  • Track 9-6Vaccine-preventable diseases
  • Track 9-7Vaccine safety in immunization programmes
  • Track 10-1Cytokines as adjuvants
  • Track 10-2Alum as an adjuvant
  • Track 10-3Immunologic adjuvants
  • Track 10-4Liposomal adjuvants
  • Track 10-5Organic adjuvants
  • Track 10-6Inorganic adjuvants
  • Track 10-7Mechanism of Action of adjuvants
  • Track 11-1Technology behind Plant Vaccines
  • Track 11-2Antiviral Resistance
  • Track 11-3Immune Response
  • Track 11-4Agrobacterium mediated transformation
  • Track 11-5Chloroplast Transformation
  • Track 11-6Dengue Vaccine
  • Track 11-7Vaccine from Tobacco plant
  • Track 12-1Intralymphatic Vaccination
  • Track 12-2Optimize Dose Schedule
  • Track 12-3CD4+ and CD8+ T cell responses
  • Track 12-4Monoclonal Antibodies
  • Track 12-5Vaccines for routine and selective use
  • Track 12-6Routes of Vaccine Delivery
  • Track 13-1Passive surveillance systems
  • Track 13-2Active Surveillance Activities
  • Track 13-3Surveillance of vaccination coverage
  • Track 13-4Disease surveillance
  • Track 13-5Vaccine pharmacovigilance
  • Track 13-6Control of Infectious Diseases
  • Track 14-1Antimicrobials and Latest Innovations
  • Track 14-2Advisory Committee on Immunization Practices
  • Track 14-3Organizing vaccines and its uses Information Centres
  • Track 14-4Vaccines and Pharma plans
  • Track 14-5Pharmaceutical Sales
  • Track 14-6Vaccines Development Companies
  • Track 15-1Information on the Benefits and Risks of Immunization
  • Track 15-2Cost Ratio of Immunization
  • Track 15-3Vaccine schedules and administration
  • Track 15-4Integrity of the immunization program
  • Track 15-5Global Vaccination and challenges
  • Track 15-6Global and Regional Immunization
  • Track 15-7Future studies
  • Track 16-1Edible Vaccines
  • Track 16-2Common vaccinations given by mucosal route
  • Track 16-3Mucosal Vaccines Delivery
  • Track 16-4Challenges in mucosal vaccine design
  • Track 17-1Bordetella Vaccine
  • Track 17-2Rubella Vaccine
  • Track 17-3OPV Vaccine
  • Track 17-4Meningococcal /Menactra Vaccines
  • Track 17-5Smallpox Vaccine
  • Track 17-6Chickenpox Vaccine
  • Track 17-7Cholera Vaccine
  • Track 17-8Measles Vaccines
  • Track 17-9Rotavirus Vaccine
  • Track 18-1HIV Vaccine Strategies
  • Track 18-2T cell-based vaccines
  • Track 18-3B cell-based vaccines
  • Track 18-4Innate & Mucosal Immunity
  • Track 18-5Viral Vaccine Vectors
  • Track 19-1 oral vaccination
  • Track 19-2Immersion vaccination
  • Track 19-3Injection vaccination
  • Track 19-4Vaccination Techniques
  • Track 20-1MMR Vaccine and Travel
  • Track 20-2Traveler’s diarrhea
  • Track 20-3Routine Immunizations for travel
  • Track 21-1TB vaccine development
  • Track 21-2Scientific challenges facing the TB vaccine field
  • Track 21-3Next Generation TB Vaccines and Vaccine Concepts
  • Track 22-1Safety or efficacy of a veterinary medicine
  • Track 22-2Animal health outcomes
  • Track 22-3Recent Advances in Animal Vaccination
  • Track 22-4Current status of veterinary vaccines
  • Track 22-5Vaccines for Livestock Diseases
  • Track 23-1Delivery methods
  • Track 23-2Next generation DNA Vaccines
  • Track 23-3Recombinant Vaccines
  • Track 24-1Vaccine Research in Europe
  • Track 24-2Therapeutic vaccination for auto immune diseases
  • Track 24-3Vaccine Immunoinformatics
  • Track 24-4Vaccine Management & Quality Assurance
  • Track 24-5Vaccine clinical trials
  • Track 24-6Vaccines discovery, development & formulation